Our Pipeline

Our integrated approach is uniquely positioned to transform immunotherapies for cancer. Our initial areas of development will focus on the parallel advancement of Umoja’s core platforms with the goal of integrating these synergistic platforms into therapeutic regimens that can be delivered to any patient, with any tumor, at any time.


Our lead candidate programs are:

VivoVec UB-VV100 engineering cells with RACR/CAR

For hematological tumors

TumorTag UB-TT170 with Ex Vivo TagCAR T cells

For solid tumors

Umoja is driven by a bold and unified vision to transform cancer treatment and improve quality of life. We are a diverse group of drug development experts, scientists, and researchers that are skilled, passionate, persistent, and committed to finding a way to break through the current challenges seen in immuno-oncology today.